

Life Sciences Alumni

2024-25 Cohort

Apricity Health | Houston, TX

Apricity Health offers a precision health platform that merges two health verticals, care delivery and drug discovery, to enhance patient care and utilize longitudinal patient data to identify drug resistance drivers and biomarkers for therapeutic development.

CEO: Lynda Chin

Website: apricity-health.com

BreakBio Corp | Miami, FL

BreakBio aims to provide personalized cancer medicine for solid tumors through an AI/ML-driven platform by identifying ~30 tumor antigen targets per patient and manufacturing ~30 targeting peptides.

CEO: Roy de Souza

Website: breakbio.com

CartaBio | Boston, MA

CartaBio's platform uses cell-centric technology with generative AI to spatially resolve cell states in order to enhance therapeutic success. Their lead technology is focused on improving T cell models for immune cell therapy development.

CEO: Rob Yang

Website: cartabio.ai

Cellinfinity Bio | New Haven, CT

Cellinfinity Bio generates novel cell and gene therapies for solid tumors and autoimmune diseases by identifying therapy-enhancing drug targets through large, whole-genome CRISPR screens of CAR-T and CAR-NK cells.

CEO: Premal Patel

Website: cellinfinitybio.com

Ceramedix | New York, NY

Ceramedix aspires to treat diabetic retinopathy and other microvascular injury-related diseases by administering subcutaneously a first-in-class anti-ceramide antibody that selectively targets and disrupts endothelial cell injury.

CEO: Charles Dimmler

Website: [linkedin.com/company/ceramedix/](https://www.linkedin.com/company/ceramedix/)

Cloverleaf Bio | New Haven, CT

Cloverleaf Bio looks to improve patient outcomes in oncology by inhibiting cancer growth with a single therapeutic molecule using a new platform of engineered tRNA therapeutics.

CEO: Austin Draycott

Website: cloverleafbio.com

Coastar Therapeutics | San Diego, CA

Coastar Therapeutics looks to improve drug delivery for cancer immunotherapies and gene therapies through their proprietary Erythrocyte Derived Membrane (EDM) platform.

CEO: Eddie Chung

Website: coastartherapeutics.com

DoriNano | Boston, MA

DoriNano's novel DNA origami drug delivery platform aims to improve drug stability, targeting, and efficacy. Their nanoparticles load a diverse cargo of vaccines, immunotherapies, siRNA/mRNAs, and more to treat cancer, autoimmune diseases, and infectious diseases.

CEO: Claire Zeng

Website: dorinano.com

IDP Pharma | Barcelona, Spain

IDP Pharma is developing cancer therapies that target intrinsically disordered proteins and modulate intra-protein interactions with a lead target of cMyc, a key disease driver in 70% of cancers.

CEO: Santiago Esteban

Website: idp-pharma.com

Koi Biotherapeutics | Boston, MA

Koi Biotherapeutics' CAR-Enhancer platform uses a novel protein therapeutic that selectively binds to any CAR T-cell therapy to enhance activity, prevent exhaustion, and promote development into memory cells.

CEO: Hamid Mahini

Website: koibiotherapeutics.com

Modulate Bio | Boston, MA

Modulate Bio is developing fine-tuned neuro-medicines for GABAA-linked CNS disorders (e.g., essential tremor, epilepsy, and anxiety) using its next-generation platform that can elucidate how compounds interact with brain receptors.

CEO: Andrew Thomson

Website: modulatebio.com

Olfera | San Francisco, CA

Olfera utilizes a novel technology that models the three-compartment olfactory system to enable screening and development of drugs that can traverse the olfactory epithelium to be delivered directly to the brain.

CEO: Parnian Lak

Website: olferatx.com

Plantibodies | Paris, France

Plantibodies is developing a novel, plant-based oral encapsulation method for targeted delivery of biologics into the gastrointestinal tract for the treatment of GI diseases such as colorectal cancer.

CEO: Pierre Bauër

Website: plantibodies.tech

Rasayana Therapeutics | Boston, MA

Rasayana Therapeutics is utilizing the gut-organ axis to develop gut-targeted treatments for chronic diseases. Their lead candidate is a first-in-class, gut-restricted biologic that inhibits inflammation and intestinal permeability in ulcerative colitis.

CEO: Vidisha Mohad

Website: rasayanatherapeutics.com

Rejuvenation Technologies | Mountain View, CA

Rejuvenation Technologies looks to improve quality of life and the human lifespan by treating chronic pulmonary, hepatic, and hematopoietic diseases through telomere extension using its mRNA delivery technology.

CEO: John Ramunas

Website: rejuvenationtech.com

Script Biosciences | Yardley, PA

Script Biosciences is developing a dual-therapy platform that combines a CRISPR-based gene editing system with lipid nanoparticle carriers for delivery of genetic materials to target organs, including the brain.

CEO: Anil Namboodiripad

Website: scriptbiosciences.com

SEED Therapeutics | King of Prussia, PA

SEED Therapeutics utilizes novel Molecular Glue compounds that facilitate ubiquitination and targeted protein degradation of previously undruggable proteins in cancer, neurodegenerative disease, and more.

CEO: Lan Huang

Website: seedtherapeutics.com

Sensible Biotechnologies | Oxford, United Kingdom

Sensible Biotechnologies is developing a platform to improve upon production, quality, and efficacy of diverse mRNA therapeutics using its unique, cost-effective, and scalable cell-based production pipeline.

CEO: Miro Gasparek

Website: sensible.bio

SyntheX | San Francisco, CA

SyntheX is utilizing a novel cell-engineering strategy to target previously inaccessible disease-causing proteins by leveraging protein-protein interaction inhibition and protein degradation.

CEO: Maria Soloveychik

Website: synthelabs.com

Tessel Bio | Cambridge, MA

Tessel Bio's AI-driven drug discovery platform utilizes unique patient-derived tissues to model chronic disease. Their current pipeline aims to target neutrophilic inflammation and tissue remodeling in COPD, IBD, and more.

CEO: Naren Tallapragada

Website: tessel.bio

2023-24 Cohort

4M Therapeutics | Skillman, NJ

4M Therapeutics is developing new treatments for neurological and psychiatric disorders. The drug discovery platform identifies and optimizes candidate therapies by evaluating their effects on living human brain cells. The lead asset is safer and more potent than lithium, the current standard of care for bipolar disease.

CEO: Pablo Lapuerta

Website: 4mtx.net

Ambulero | Miami, FL

Ambulero is advancing a first-in-class cell and gene therapy platform to address severe vascular disease and non-healing wounds, where the standard of care is often amputation. The platform utilizes a cell adhesion model (E-selectin) to activate the healing and regeneration of damaged vascular tissue.

CEO: Robert Buchanan

Website: ambulero.com

Ataraxis AI | New York, NY

Ataraxis AI is developing prognostic and predictive digital diagnostic assays that integrate multi-modal data to deliver accurate and patient-specific predictions about therapeutic outcomes. This solution may replace molecular diagnostics, enabling clinicians to develop more effective and personalized treatment plans across several disease stages, starting with early-stage breast cancer.

CEO: Jan Witowski

Website: ataraxis.ai

Atticus Pharma | Greenville, SC

Atticus Pharma is developing its innovative Z-pod® technology for topical drug delivery. Z-pods enhance bioavailability—and thereby efficacy—of a wide range of topically applied APIs. Our lead products are AEA-loaded Z-pods for cutaneous manifestations of lupus and Y200-loaded Z-pods for alopecia.

CEO: Gautam Ghatnekar
Website: atticuspharma.com

Avstera Therapeutics | Malvern, PA

Avstera Therapeutics is developing treatments for metastatic solid tumors that address key immunological challenges observed in the tumor microenvironment. Specifically, the lead Ph1 ready asset, a highly specific HDAC6 inhibitor, administered in combination with PD-1 inhibitor pembrolizumab, has the potential to suppress polarization of macrophages towards pro-tumoral phenotypes to increase overall response rate and extend survival.

CEO: Karthik Musunuri
Website: avstera.com

Calder Biosciences | New York, NY

Calder Biosciences is developing the next-generation of recombinant subunit protein vaccines to prevent infection diseases. Its patented 3D-Vaxlock™ technology drives conformational stabilization, locking viral subunit antigens into their most potent conformation and exposing epitopes that elicit substantially more neutralizing antibodies & more protective immune responses. This approach drives development of vaccines that are safe, protective, tolerable, durable, and low-cost, while significantly reducing (or eliminating) cold chain requirements.

CEO: Christopher Marshall
Website: calderbiosciences.com

Eucalyptus Bio | San Carlos, CA

Eucalyptus Bio is unlocking the power of gene editing across thousands of base-pairs. Their unique approach allows a single therapeutic to restore healthy gene function despite the many different mutations which can comprise a single genetic disease, unlocking hundreds of new disease targets.

CEO: Chris Hackley
Website: crisp-hr.com

GlyTherix | Macquarie Park, Australia

GlyTherix is a clinical stage targeted radiotherapy company developing a first-in-class therapeutic. Miltuximab® is an antibody that binds to Glypican-1, a cell surface target that occurs within many solid tumors including prostate, bladder and pancreatic cancers. Miltuximab® is currently uses beta emitters with an alpha emitter version in development.

CEO: Brad Walsh

Website: glytherix.com

IMNEWRUN | Suwon-si, South Korea

IMNEWRUN is developing TRANSMAB®, a novel blood-brain barrier (BBB)-penetrating platform designed to deliver therapeutic antibodies selectively to the brain with high bioavailability. Their first therapeutic program, INR301, is a first-in-class BBB-penetrating anti-PD-L1 antibody, representing a new treatment paradigm for Alzheimer's disease by restoring immune balance in the brain.

CEO: Han-Joo Kim

Website: imnewrun.com

InGel Therapeutics | Allston, MA

InGel Therapeutics is a regenerative medicine company developing novel cell-based therapies to restore vision across patients suffering from all forms of retinal degeneration and blindness. The lead asset (IGT-001) is a pure rod-based retinal stem cell that secretes neurotrophic factors, encapsulated within a biomimetic injectable hydrogel, for retinitis pigmentosa.

CEO: Pierre Dromel

Website: ingeltx.com

Kadence Bio (formerly Kanna Health) | London, United Kingdom

Kanna Health is a clinical stage biotech looking to bridge the 'intimacy gap' by developing the first FDA-approved treatment for premature ejaculation.

CEO: John Boghossian

Website: kanna.health

Matrisome Bio | Cambridge, MA

Matrisome Bio is thinking “outside the cell” and building an extracellular matrix (ECM) targeting and discovery platform. The platform leverages the unique properties of disease-associated ECM for the treatment of chronic disease. With an initial focus on oncology, they are developing ECM-specific nanobodies optimized for highly targeted delivery of therapeutic payloads to disease sites.

CEO: Noor Jailkhani

Website: matrisomebio.com

OraLiva | New York, NY

Oraliva Oral ONC-InCyt provides non-invasive, clinically validated, AI-assisted diagnostics for screening oral lesions (oral lichenoid lesions, cavity cancers, oral epithelial dysplasia). These innovative diagnostic solutions backed by largest US dental provider deliver highly accurate diagnostic information to dental / medical providers for first time establishing a new standard of care.

CEO: Joe Sebastian

Website: oraliva.com

Pando Bioscience | Boston, MA

Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.

CEO: Will Cao

Website: pando.bio

Promise Bio | Tel Aviv, Israel

Promise Bio is uncovering new biological insights to drive clinical diagnostics supporting precision-based treatment of autoimmune diseases and drug discovery. Their proprietary

computational platform, PROMISE, generates unique proteomic-based profiles. Machine learning algorithms are applied to translate these profiles into actionable insights and reports.

CEO: Ronel Veksler

Website: promisebio.co

Quanmol Tech | Hillsborough, CA

QuanMol Tech is developing an AI-driven drug design (AIDD) platform that uniquely blends computational chemistry with physics-informed AI to optimize chemical product design, including drug design. This technology applies a validated quantitative methodology to predict complex interactions between enzymes & small molecules and provides automated rationale generation.

CEO: Xingyu Shen

Website: quanmol.com

resistanceBio | Menlo Park, CA

resistanceBio is unlocking a new generation of cancer therapies, designed with drug resistance in mind, to overcome the #1 cause of cancer deaths. Their proprietary platform leverages billions of cells in long-term evolution to predict how cancer will evolve to resist new therapies. Top pharmaceutical companies are partnering with resistanceBio to select lead drugs, indications, and patient populations that result in extended efficacy and improved patient outcomes. The ability to mimic cancer's evolution in humans for the first time, is revealing novel biomarkers, druggable targets, and a path to turning cancer into a manageable disease.

CEO: Nicholas Goldner

Website: resistance.bio

Serinus Bio | New York, NY

Serinus Bio is designing novel treatments for the 9M people that die of cancer drug resistance every year. Their active-learning AI platform reveals major market opportunities by identifying shared vulnerabilities across resistant patient populations that are otherwise too small or insular to motivate drug development programs.

CEO: Adam Yaari

Website: serinus.bio

Tezcat Biosciences | New York, NY

Tezcat Biosciences is developing receptor-independent drug delivery technology to provide treatment alternatives for patients harboring mutant RAS cancers. Tezcat's proprietary protein-drug conjugates act like a Trojan Horse, gaining access to cancer cells through a metabolic protein scavenging process and then releasing conjugated therapeutic payloads.

CEO: Craig Ramirez

Website: tezcat.co

Vector Bioscience | Cambridge, United Kingdom

Vector Bioscience Cambridge is a ML-enabled company developing a first-in-class RNA-delivery platform designed to protect and deliver any existing cargo, including macromolecule therapeutics and small-molecule drugs directly to a tumor with a controlled release, resulting in improved efficiency and minimized side effects.

CEO: Lluna Gallego

Website: vectorbiocam.com

Vivtex | Cambridge, MA

Vivtex leverages their high-throughput gut-on-a-chip platform (GI-ORISTM) with proprietary AI algorithms and formulations to optimize pharmaceuticals for oral bioavailability. From Robert Langer's (MIT) and Giovanni Traverso's (MIT/Harvard) labs, Vivtex is revolutionizing the market for biologic therapies, creating oral alternatives for both existing high-value biologic candidates and new oral biologics.

CEO: Maureen Deehan

Website: vivtex.com

2022-23 Cohort

Amplified Sciences | West Lafayette, IN

Amplified Sciences is a clinical stage in vitro diagnostics company that accurately detects debilitating diseases sooner, starting with pancreatic cancer, by using a portfolio of fully integrated point-of-care assays that minimize sample volumes.

CEO: Diana Caldwell

Website: amplifiedsci.com

CellChorus | Houston, TX

CellChorus is a dynamic single-cell analysis company that uses AI to evaluate thousands of microscopy videos in parallel, optimizing therapeutic development, manufacturing and delivery through functional assessments of the immune system.

CEO: Dan Meyer

Website: cellchorus.com

Haystack Oncology | Baltimore, MD

Haystack Oncology evaluates circulating tumor DNA with ultrasensitive next-generation sequencing to identify residual, recurrent, and resistant disease in cancer patients, providing best-in-class personalized testing that prompts proactive clinical interventions to dramatically improve patient outcomes.

CEO: Dan Edelstein

Website: haystackoncology.com

HDAX Therapeutics | Ontario, Canada

HDAX Therapeutics is developing a new class of disease-modifying therapeutics for neurological diseases with axonal dysfunction, starting with chemotherapy-induced peripheral neuropathy in cancer patients. Through our novel bitopic binding mechanism targeting HDAC6, we aim to create the first ever disease-modifying therapy for these patients.

CEO: Nabanita Nawar

Website: hdaxtx.com

iQure Pharma | Princeton, NJ

iQure Pharma treats neuropathic and chronic, severe pain without the use of opioids, developing breakthrough therapeutics with a novel mechanism of action to provide more efficacious and safer treatment to hundreds of millions of patients worldwide (~35M US).

CEO: Pawel Zolnierczyk

Website: iqurepharma.com

Maxwell Biosciences | Austin, TX

Maxwell Biosciences develops a breakthrough “one drug for many bugs” platform that targets the unchanging cell membrane, ensuring resulting therapeutics are highly potent, safe and effective against all strains/mutations of enveloped viruses (pan-coronavirus, pan-influenza, etc.), drug resistant bacteria, fungi, yeast and biofilms.

CEO: Joshua McClure

Website: maxwellbiosciences.com

Nano PharmaSolutions | San Diego, CA

Nano PharmaSolutions improves the solubility of small molecule drugs using a proprietary nanoparticle platform, enhancing the bioavailability of existing therapeutics for biopharmaceutical customers.

CEO: Kay Olmstead

Website: nanopharmasolutions.com

Pandorum International | San Carlos, CA

Pandorum International utilizes a tissue engineering platform based in multi-omics computational biology, 3D printing, and exosome engineering to restore healthy function to diseased tissues, with pre-clinically validated indications in the cornea (blindness), lung (respiratory distress syndrome), and liver (non-alcoholic Steatohepatitis).

CEO: Tuhin Bhowmick

Website: pandorumtechnologies.in

Phinomics | San Carlos, CA

Phinomics has pioneered a universal “stage zero” diagnostic by isolating and sequencing the “circulome”, uncovering previously hidden circular DNA signatures that are early markers of genetic and environmental change for many cancer types, beginning with urologic cancer.

CEO: Massa Shoura

Website: phinomics.com

Protabit | Pasadena, CA

Protabit has developed an AI-based protein engineering platform that optimizes the properties of antibodies and therapeutic proteins for the pharmaceutical and biotech industries, with applications in COVID-19 and oncology.

CEO: Barry Olafson

Website: protabit.com

Protai | Tel Aviv, Israel

Protai leverages AI and proteomics to develop therapeutics based on the identification of post-translational modifications and protein-protein interactions, accurately predicting targets and responses for overcoming drug resistance.

CEO: Eran Seger

Website: protai.bio

QurCan Therapeutics | Toronto, Canada

QurCan Therapeutics developed the TERP lipid nanoparticle platform to overcome drug delivery challenges including immunogenicity, low stability, rapid clearance, and liver accumulation for patients with cancers or central nervous system diseases, enhancing the safety and effectiveness of therapeutics.

CEO: Mohammad Ali Amini

Website: qurcan.com

Sachi Bioworks | Louisville, CO

Sachi Bioworks developed the revolutionary AI-powered Nanoligomer™ platform for high-throughput drug discovery, design, development, and validation in order to create first-in-class therapeutic assets for space medicine and personalized medicine.

CEO: Anushree Chatterjee

Website: sachibio.com

siRNAgen Therapeutics | Daejeon, South Korea

siRNAgen developed a proprietary siRNA platform that enables extrahepatic delivery to previously inaccessible organs, such as the brain and lung, to develop breakthrough therapeutics for chronic diseases with high unmet needs as well as cosmetics for hair-loss.

CEO: June Park

Website: sirnagen.com

UbiquiTx | New York, NY

UbiquiTx utilizes a deep learning AI/ML platform to develop a novel class of mRNA therapeutics that selectively degrade historically undruggable targets, including post-translational proteins and initially targeting transcription factors that suppress the immune response.

CEO: Mathew Barnett

Website: ubiquitx.com

Woven Orthopedic Technologies | Manchester, CT

Woven Orthopedics Technologies developed a patented and clinically proven Ogmend® sleeve, which serves as a first-in-class device for orthopedic surgeons to increase implant fixation strength and promote bony ingrowth for optimal healing in compromised fixation scenarios.

CEO: Brandon Bendes

Website: wovenorthopedics.com

2021-22 Cohort

Alixia | Palo Alto, CA

Alixia is a platform therapeutics company that targets tumor heterogeneity. Our platform integrates developmental biology, biophysics and computational biology to identify molecules that disrupt the metabolic and inflammatory triggers within the tumor, enabling effective and durable cancer treatments.

CEO: Helen Chen

Website: alixia.com

Celestial Therapeutics | Irvine, CA

Celestial Therapeutics is developing a new class of mRNA vaccines and therapeutics using its proprietary Stellar-mRNA platform to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The platform significantly reduces reactogenicity while enhancing immunogenicity for safe, effective, and durable treatment in a variety of indications.

CEO: Ajay Gupta

Website: celestialtherapeutics.com

Cytosolix | Tolland, CT

Cytosolix is developing novel derivatives of known small molecule oral oncology drugs that selectively target cancer cells via a universal biomarker of solid tumors, acidity, significantly improving efficacy.

CEO: John Deacon

Website: cytosolix.com

Entelexo Biotherapeutics | Irvine, CA

Entelexo is developing next-generation exosome-based therapeutics to address incurable autoimmune diseases by specifically targeting autoreactive immune cells for effective treatment with mitigated side effects.

CEO: Milad Riazifar

Website: entelexo.com

Immunyx Pharma | Jerusalem, Israel

Immunyx has developed targeted neutrophil nanoparticles (TENNs) to solve the major hurdles in treating neutrophils in disease, with a focus on therapies for colitis and cancer.

CEO: Seth Salpeter

Website: immunyx.com

Inherent Biosciences | Salt Lake City, UT

Inherent Biosciences uses a next-generation sequencing and AI platform to commercialize epigenetic biomarkers for human complex disease, beginning with male infertility.

CEO: Kristin Brogaard

Website: inherentbio.com

Interface Biosciences | Palo Alto, CA

Interface Biosciences is a platform therapeutics company mining the novel chemical space of the gut microbiome to develop drugs to treat inflammatory diseases.

CEO: Hannah Wastyk

Website: interface.bio

Isla Technologies | San Carlos, CA

Isla Technologies is developing an intravascular cellular implant to deliver insulin to patients suffering from type 1 diabetes, providing precise blood glucose control and eliminating the need for insulin injections.

CEO: Sara Photiadis

Website: islatechnologies.com

Lime Therapeutics | New York, NY

Lime Therapeutics is a Memorial Sloan Kettering Cancer Center spinout using a proprietary nanotechnology drug discovery platform to create a novel class of therapeutics targeting lipid metabolism in cancer and neurodegenerative disorders.

CEO: Shardule Shah

Website: <https://limetherapeutics.com/>

MarPam Pharma | St. Paul, MN

MarPam Pharma is developing a revolutionary one-time HIV treatment that equips a patient's own immune cells with the ability to seek out and destroy HIV where it hides, thus eliminating the burdensome need for daily medications.

CEO: Maria Athanasiou

Website: marpampharma.com

Matricelf | Ness Ziona, Israel

Matricelf is developing a platform for the production and printing of functioning 3D autologous tissues (cells and matrix) for a variety of medical conditions, with an initial application in spinal cord injury.

CEO: Asaf Toker

Website: matricelf.com

myNEO | Gent, Belgium

myNEO is developing personalized cancer vaccines designed using genomic tumor fingerprints, which teach the body's defences to recognize tumor neoantigens, eliminate related cancer cells, and prevent metastasis.

CEO: Cedric Bogaert

Website: myneo.me

Myosin Therapeutics | Jupiter, FL

Myosin Therapeutics is an oncology platform company based on the untapped, druggable superfamily of molecular nanomotors with a preclinical asset.

CEO: Courtney Miller

Website: myosintherapeutics.com

OncoPrecision | New York, NY

OncoPrecision is developing Patient Micro-Avatars (PMAs) to replicate cancer patients' disease for ex-vivo screening to improve therapeutic response and drug development.

CEO: Tarek Ali Zaki

Website: oncoprecision.bio

Polaris Genomics | Rockville, MD

Polaris Genomics is a precision mental health company that is advancing the diagnosis and treatment of mental health conditions, such as PTSD, using a custom 1000-gene neuropsychiatric panel (TruGen-1) with an AI/ML bioinformatics engine (TruNorth).

CEO: Charles Cathlin

Website: polarisgenomics.com

RenBio | New York, NY

RenBio delivers DNA therapeutics that allow for the in vivo bioproduction of antibody and protein therapeutics, fundamentally changing the use and global reach of antibody and protein therapies by overcoming prior limitations in administration, duration of efficacy, dosing frequency, and cost.

CEO: Neal Padte

Website: renbio.com

Reveal Pharma | Cambridge, MA

Reveal Pharma is a clinical-stage specialty pharma company poised to transform medical insight with safer, gadolinium-free MRI contrast agents and unparalleled targeted imaging of

fibrogenesis; benefiting tens of millions of patients, accelerating development of therapeutics, and positively impacting the environment.

CEO: Vera Hoffman

Website: revealpharma.com

Think Bioscience | Boulder, CO

Think Bioscience engineers microbes to access novel chemistries for elusive drug targets.

CEO: Jerome Fox

Website: thinkbioscience.com

Waypoint Bio | New York, NY

Waypoint Bio visualizes spatial biology to power AI-designed cell therapies.

CEO: Xinchun Wang

Website: waypointbio.com

Wild Biotech | Rehovot, Israel

Wild Biotech has created an end-to-end drug discovery & development platform, translating the super-hero features of wild animals' untapped gut microbiomes into a new class of oral biologics for human diseases.

CEO: Neta Raab

Website: <https://wildbio.tech>

2020-21 Cohort

Biorchestra | Daejeon, South Korea

Biorchestra is dedicated to treating Alzheimer's disease by restoring brain cell functions using epigenetic modification. Biorchestra's RNA-based epigenetic regulator is delivered into the cytoplasm of neurons and glial cells, activating key pathways critical to their normal function and bringing about a disease-modifying effect.

CEO: Branden Ryu

Website: www.biorchestra.com

Cell Care Therapeutics | Monrovia, CA

Cell Care Therapeutics is creating a new class of medicines designed from the secretome of mesenchymal stem cells. This approach restores the function of damaged blood-tissue barriers, such as leaking blood vessels that cause major diseases in the eye, lung, central nervous system, and gut.

CEO: Nicolas Sohl

Website: www.cell-care.com

Concerto Biosciences | Allston, MA

Using a patented screening platform, Concerto Biosciences discovers microbial ensembles: combinations of microbes that heal humans and plants. The first products will treat skin diseases, allowing hundreds of millions of people to enjoy a life free from inflamed, itchy skin. Concerto plans to build microbial products that impact every aspect of human life.

CEO: Cheri Ackerman

Website: <https://www.concertobio.com/>

Evoke Neuroscience | New York, NY

Evoke Neuroscience is a data and diagnostics company focused on reducing the number of people living with treatable cognitive impairment. Evoke's platform technology leverages EEG to help doctors diagnose dementia and other brain-based disorders.

CEO: Dave Hagedorn

Website: www.evokeneuroscience.com

EVQLV | New York, NY

EVQLV develops AI engineered with life science data to accelerate the speed at which biologic therapies reach those in need. EVQLV uses AI to model evolution and rapidly generate billions of potential biologic therapies. Each one is screened to ensure high affinity, drug-like properties, as well as patentability. The result is a library of lead therapeutic candidates with a lower likelihood of downstream failure.

CEO: Andrew Satz

Website: <https://evqlv.com/>

Flexomics | Boston, MA

Flexomics provides a screening platform for large-scale simultaneous functional and genomic analyses of single cells and cell-to-cell interactions to simplify and accelerate the development of therapeutics and other high-value biologics.

CEO: Magali Soumillon

Website: <https://www.flexomics.com/>

HelpWear | Toronto, Canada

HelpWear builds a continuous clinical-grade ECG monitor, worn on a patient's bicep, that can detect anything from a minor heart occurrence to a lethal event. Long term, HelpWear aims to build the hardware to enable telemedicine, bringing ICU quality monitoring anywhere.

CEO: Andre Bertram

Website: www.helpwear.ca

Invisra | Columbus, OH

INV-102 is a novel eye drop that promotes accelerated healing through DNA repair. INV-102 is the first drug to show promise in treating ocular sulfur mustard injury, and therefore, Invisra is the first ophthalmic therapeutic company to sign a contract with BARDA to develop a medical countermeasure. BARDA is funding INV-102's commercial indication clinical trials so that INV-102 is available nationwide in case of a sulfur mustard event.

CEO: Robert Shalwitz

Website: www.invirsa.com

KayoThera | Princeton, NJ

KayoThera leverages cutting-edge discoveries to develop therapeutics for cancer patients who currently receive terminal diagnoses. Two pipeline candidates target novel biology to deplete immuno-suppressive cells from solid tumors and inhibit tumor survival mechanisms in advanced cancers. With these first-in-class, orally available small molecule therapeutics, KayoThera aims to give hope to patients with intractable cancers.

CEO: Mark Esposito

Website: www.kayothera.com

Lucy Therapeutics | Cambridge, MA

Lucy Therapeutics is a mitochondrial platform company focused on small molecule treatments for Rett Syndrome and Parkinson's Disease, leveraging a unique peripheral mitochondrial biomarker. LucyTx's platform has led to the discovery of targets which can improve central energetic dysfunctions in these diseases and address their complex organ symptomatology. LucyTx interrogates complex biology with well-defined molecules to answer key questions about the pathways critical for disease modification.

CEO: Amy Ripka

Website: www.lucytherapeutics.com

Mytide Therapeutics | Boston, MA

Mytide has developed a first-in-class bio fabrication platform (BioFAB) for synthetic peptide and protein drug discovery and clinical treatment development to overcome molecular scarcity. Our BioFABs leverage machine learning, robotics, and proprietary continuous manufacturing to construct libraries of complex bio-molecules to validate our prediction engine, BioCLOUD.ai.

CEO: Dale Thomas

Website: <https://www.mytide.io/>

PhagoMed | Vienna, Austria

PhagoMed develops precision therapies for chronic bacterial infections. Its lead program, PM-477, targets Recurrent Bacterial Vaginosis (rBV), a chronic vaginal disease that affects 100 million women across the globe. To treat rBV, PhagoMed invented a phage-based lysin that targets only the disease-causing bacteria and preserves the beneficial vaginal microbiome. The platform technology is now being extended to further chronic diseases.

CEO: Alexander Belcredi

Website: www.phagomed.com

ProteinQure | Toronto, Canada

ProteinQure is a computational platform for protein drug discovery that partners with pharma to deliver novel chemical matter. ProteinQure combines molecular simulations, machine learning, and experiments to perform structure-based drug design. These methods require less dependence on large data sets, which is relevant for novel biologics and difficult targets.

CEO: Lucas Siow

Website: www.proteinquire.com

Purview | Annapolis, MD

Purview's Expert View Platform provides immediate access to patient medical records from any (disconnected) system to enable remote diagnosis and treatment for second opinions, hospital transfers, and clinical trials.

CEO: Les Trachtman

Website: www.purview.net

Sardona Therapeutics | San Francisco, CA

Sardona Therapeutics is a preclinical biotechnology company building the leading platform to develop small molecule drugs that target RNA-binding proteins in the spliceosome, and provide patients with therapy-resistant cancers novel treatment options. Sardona is advancing a robust pipeline of multiple, internally-developed programs, including the lead program, that has particular activity in mTORC1-pathway activated breast cancers and other solid tumor indications.

CEO: Martina Roos

Website: <https://sardonatx.com>

VastBiome | San Carlos, CA

VastBiome is prospecting novel molecules from the human gut microbiome and developing them into standalone therapeutics. The company is generating the largest database linking gut microbes to their chemical and immune axes of host response. Moving from identification and annotation of organisms, genes, and metabolites to design, we study these relationships to construct immunoregulatory drugs with specified functions through synthetic gene expression.

CEO: Kareen Barghouti

Website: www.vastbiome.com

Wasaba Technologies | New York, NY

Wasaba provides prognostic software for medical providers that predicts the recurrence of melanoma to solve the problem of under-treatment and allow patients access to life-saving adjuvant therapies.

CEO: Christopher Barnes

Website: <https://www.wasabalttd.com>

2019-20 Cohort

A2A Pharma | New York, NY

A2A Pharmaceuticals leverages proprietary computational systems to accelerate the development of novel drugs for life-threatening diseases like cancer, bacterial infections and muscular dystrophy. The company uniquely designs novel libraries of target-specific molecules rather than screening through existing databases and helps advance high-quality programs through the clinic...

CEO: Dr. Sotirios Stergiopoulos

Website: <https://www.a2apharma.com>

Algen Biotechnologies | San Francisco, CA

Algen Biotechnologies is building a CRISPR-based screening platform to decode functional gene networks of complex diseases and accelerate cancer therapeutics discovery. Our platform allows for the construction of high-resolution disease maps and identification of novel drugs that selectively reverse cancer signaling while minimizing adverse events in healthy cells and tissue.

CEO: Chun-Hao Huang

Website: <https://www.algenbio.com/>

BioROSA | Boston, MA

BioROSA is developing a blood-based diagnostic and therapeutic platform for Autism Spectrum Disorder (ASD) and related pathologies. BioROSA's technology combines a novel targeted metabolic approach with machine learning to achieve superior accuracy and potentially shrink diagnostic timelines by over three years.

CEO: John Slattery

Website: <https://www.biorosa.com/>

C2i Genomics | New York, NY

C2i Genomics is developing a platform to detect and monitor tumor lesions in a patient's standard blood sample, thus enabling rapid treatment decision-making based on real-time information. The technology leverages proprietary mathematical inference models and machine

learning techniques, which provide quantification of circulating tumor DNA with 100X higher sensitivity than current methods.

CEO: Asaf Zviran

Website: <https://www.c2i-genomics.com/>

Cytonus Therapeutics | San Diego, CA

Cytonus Therapeutics is developing a cell-based platform technology focused on immuno-oncology and gene therapies for devastating and rare diseases. Cytonus' technology leverages enucleated cells that can carry multiple therapeutic payloads, bypassing issues and side-effects associated with conventional drug delivery systems.

CEO: Remo Moomiaie

Website: <https://www.cytonus.com/>

Immunai | New York, NY

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

CEO: Noam Solomon

Website: <https://www.immunai.com/>

Neochromosome | New York, NY

Neochromosome is using synthetic biology technologies to create entire chromosomes designed de novo to be modular and orthogonal to the host cell. The approach can help create new products from cells with engineered genomes across a variety of biotechnology applications, from medicine to agriculture to materials to biomanufacturing.

CEO: Leslie Mitchell

Website: <https://www.neochromosome.com/>

Nirova BioSense | New York, NY

Nirova BioSense is developing the first implantable optical nanosensor enabling early detection of cancer and other diseases. The minimally-invasive platform technology can measure cancer biomarkers and protein levels and interface with wearable devices.

CEO: Donna Rounds

Website: <https://www.nirovabio.com/>

Octagon Therapeutics | Boston, MA

Octagon Therapeutics is a drug discovery platform using systems biology and engineered nutrient inputs to identify novel metabolic drug targets for autoimmune disease, oncology, and bacterial infection. The technology highlights metabolic vulnerabilities in rapidly proliferating cell populations using a computational approach and can identify drug candidates that show no activity in traditional screens.

CEO: Isaac Stoner

Website: <https://www.octagontx.com/>

Onconetics Pharmaceuticals | San Francisco, CA

Onconetics Pharmaceuticals is a synthetic biology company using its gene therapy platform to stimulate the immune system against cancer. The technology is based on selective expression of therapeutic proteins within cancerous cell types and not surrounding healthy tissue, thus addressing the issue of side effects associated with cancer therapies.

CEO: Luke Gruenert

Website: <https://www.onconetics.com/>

PhAST Diagnostics | Boston, MA

PhAST is an AI diagnostic startup developing computer vision technology for rapid pathogen identification and antimicrobial susceptibility testing directly from patient samples. The technology provides clinical decision support for doctors, workflow improvement for hospitals, and accelerates drug development for pharma companies.

CEO: Kwangmin Son

Website: <http://phastdiagnostics.com/>

Prohibix | Philadelphia, PA

Prohibix is creating a disease-modifying therapeutic platform targeting tissue degeneration in patients suffering from diseases such as cardiovascular disease, osteoarthritis, and chronic ulcers. Their patented injectable bio-gel technology allows for the local and sustained delivery of high concentrations of tissue protecting compounds to target areas throughout the body.

CEO: Brendan Purcell

Website: <https://prohibix.com>

QSM Diagnostics | Boston, MA

QSM Diagnostics is fundamentally changing how bacterial infections are diagnosed and treated by exploiting bacterial communication (quorum sensing molecules) and virulence factors as biomarkers. The patented easy to use platform developed by QSM Diagnostics provides point-of-care diagnostic test results for bacterial infections in 2 minutes rather than the 2-3 day turnaround of standard tests, which allows doctors to provide better treatment and help mitigate the spread of antimicrobial resistance. The initial product line is being developed for the companion animal market, with a dog ear infection test set to launch in Q3 2020.

CEO: Edgar Goluch

Website: <https://www.gsmdiagnostics.com/>

Quantumcyte | Sunnyvale, CA

Quantumcyte is developing a technology to decrease the delivery time of a personalized drug therapy protocol to oncologists and patients from 4-6 weeks to one week. This automated platform combines digital pathology data with genomic data using AI and ML, delivering a specific treatment plan regardless of cancer type or stage.

CEO: John Butler

Website: <https://www.quantumcyte.com/>

SFA Therapeutics | Jenkintown, PA

SFA Therapeutics is developing treatments for chronic inflammatory diseases using substances found in the human body to reduce genotoxicity and immuno-suppression. The therapeutic

portfolio addresses a range of diseases such as arthritis, inflammatory bowel disease, psoriasis, liver cancer, and leukemia.

CEO: Dr. Ira C. Spector

Website: <https://www.sfatherapeutics.com/>

SiDx | Seattle, WA

SiDx is modernizing blood testing using patented silicon photonic biosensors and specialized surface chemistry that returns blood typing results in a fraction of the time. SiDx's innovation conserves universal blood units and speeds turnover for overcrowded emergency departments.

CEO: Eric Larsen

Website: <https://www.sidx.com>

Statera Therapeutics | Hamden, CT

Statera Therapeutics is developing a unique immunotherapy delivery platform addressing autoimmune diseases. Statera's engineered polymer nanoparticle delivers multiple therapeutic payloads (antigen/proteins and small molecule drugs) to targeted cells in a preferred sequence to elicit proper immune response in autoimmunity.

CEO: Philip Kong

Website: <https://www.statera-therapeutics.com/>

Synthis | New York, NY

Synthis is developing a pipeline of novel targeted immuno-oncology therapies to reverse immune suppression in cancer patients. Instead of directly killing the tumor using a cytotoxic payload, Synthis is employing antibody-drug conjugate technology in a novel way to restore immune-mediated tumor clearance.

CEO: Dori Thomas-Karyat

Website: <https://www.synthistx.com/>

Wesper | New York, NY

Tatch is the first company to provide wireless, comfortable, and accurate at-home sleep tests, based on proprietary flexible sensor technology. This technology connects patients and providers, closing the loop on an otherwise fragmented diagnostic and treatment process and enabling effective diagnosis and management of sleep-related disorders.

CEO: Amir Reuveny

Website: <https://wesper.co>

2018-19 Cohort

EggXYt | Jerusalem, Israel

eggXYt's CRISPR based technology makes it possible to identify the sex of livestock eggs/embryos before they are incubated or reared. In poultry, eggXYt is working with leading egg producers to introduce ethical eggs that eliminate the process of sexing and the disposal of male chicks allowing 7 billion male layer chicken eggs to be redirected to the egg market annually. eggXYt has early revenue for its solution from the bovine market and is close to securing the same in the poultry market. *The startup represented here is a graduate of Endless Frontier Labs' predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.

CEO: Yehuda Elram

Website: <https://www.eggxyt.com/>

MapNeuro | Cold Spring Harbor, NY

MapNeuro uses molecular methods to generate brain-wide maps of neuronal connectivity and gene expression at the cellular level. MapNeuro is now using these technologies to build a new in-vivo discovery platform for neurodegenerative and psychiatric diseases. *The startup represented here is a graduate of Endless Frontier Labs' predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.

CEO: Alexander Vaughan

Website: <https://www.mapneuro.com/>

Prime Discoveries | New York, NY

Prime Discoveries is The Microbiome Discovery Company. Prime uses AI to discover patterns in the microbiome and is the first to approach clinical grade accuracy for several gut diseases, subtypes, and confounding diseases. Prime is also expanding into colorectal cancer given several recent breakthroughs. Prime will begin by commercializing clinical tests and is beginning validation studies to launch the first clinical microbiome panel for gut diseases, followed by colorectal cancer. *The startup represented here is a graduate of Endless Frontier

Labs' predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.

CEO: Eugene Joseph

Website: <https://www.primediscoveries.com/>

Redesign Science | New York, NY

Redesign Science is a computational drug discovery company focusing on lead discovery against challenging and emerging drug targets, including protein-protein interactions. Their platform technology uses dynamic simulation at the atomic level to detect druggability and to guide the precise molecular design of novel therapeutic candidates. *The startup represented here is a graduate of Endless Frontier Labs' predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.

CEO: David Rooklin

Website: <https://www.redesignscience.com/>

Regenosine | Jersey City, NJ

Regenosine is developing a first-in-class disease modifying regenerative therapy for Osteoarthritis (OA). Their injectable slow-release adenosine formulation regenerates the articular cartilage and potentially delays the need for joint replacement procedures. *The startup represented here is a graduate of Endless Frontier Labs' predecessor program, called Creative Destruction Lab-New York City, operated by NYU in partnership with University of Toronto during 2018-2019. The Endless Frontier Labs has no current engagement or affiliation with the Creative Destruction Lab.

CEO: Sid Angle

Website: <https://www.regenosine.com/>

Strand Therapeutics | Boston, MA

Strand Therapeutics is pioneering programmable mRNA gene therapies. Traditional mRNA therapies simply express encoded proteins inside the body. Strand's mRNA programming

technology can design mRNA capable of entering cells, sensing the cell's identity, and then execute the appropriate therapeutic program. Their technology, invented at MIT by the founders and advisors, is the first of its kind in the mRNA field and is positioned to leapfrog existing mRNA drugs currently under development in immuno-oncology, cell therapy, immunology, and rare disease.

CEO: Jake Becraft

Website: <https://www.strandtx.com/>
